Pharma

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

ImmunoGen, Inc. , a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that it intends to offer, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public offering. ImmunoGen expects to grant the underwriters a thirty day option to purchase up to 750,000 additional shares to cover over-allotments, if any.

Today in Popular Press...keeping you current

Two Delivery Systems Win Baldrige Award
HealthDataManagement, 12/17/09

A holiday message from AHA President and CEO Rich Umbdenstock
American Hospital Association News, 12/11/09

Nursing I.T. Award Deadline Dec. 2
HealthDataManagement, 12/10/09